ResearcherGarvan Institute of Medical ResearchNo recent work listed
Jennifer Man
Matched on OpenAlex author ID A5113866648. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2018: 2 papers · 2019: 2 papers · 2020: 1 paper
Papers 5
- Fats and Mets, KRAS-Driven Lipid Dysregulation Affects Metastatic Potential in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-3082↗
- Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy. First author DOI 10.1111/febs.15011↗
- PAK inhibition by PF-3758309 enhanced the sensitivity of multiple chemotherapeutic reagents in patient-derived pancreatic cancer cell lines. Co-author PMID 31312349↗
- The PAK Inhibitor PF-3758309 Promotes the Inhibitory Effects of Multiple Chemotherapeutic Reagents on Patient-Derived Pancreatic Cancer Cell Lines Co-author DOI 10.20944/preprints201809.0322.v1↗
- The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/diseases6040103↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Marina Pajic · 5 shared papers, 2018–2020 · strength 0.59
- Paper Fats and Mets, KRAS-Driven Lipid Dysregulation Affects Metastatic Potential in Pancreatic Cancer. DOI 10.1158/0008-5472.can-20-3082↗
- Paper Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to thera… DOI 10.1111/febs.15011↗
- Paper PAK inhibition by PF-3758309 enhanced the sensitivity of multiple chemotherapeutic reagents in patient-derived pancreat… PMID 31312349↗
- Ashleigh Parkin · 4 shared papers, 2018–2019 · strength 0.40
- Paper Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to thera… DOI 10.1111/febs.15011↗
- Paper PAK inhibition by PF-3758309 enhanced the sensitivity of multiple chemotherapeutic reagents in patient-derived pancreat… PMID 31312349↗
- Paper The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. DOI 10.3390/diseases6040103↗
- Paul Timpson · 2 shared papers, 2018–2019 · strength 0.22
- Anthony Michael Joshua · 1 shared paper, 2020 · strength 0.19
- Hong Zhen He · 2 shared papers, 2018–2019 · strength 0.18
- Paper PAK inhibition by PF-3758309 enhanced the sensitivity of multiple chemotherapeutic reagents in patient-derived pancreat… PMID 31312349↗
- Paper The PAK Inhibitor PF-3758309 Promotes the Inhibitory Effects of Multiple Chemotherapeutic Reagents on Patient-Derived P… DOI 10.20944/preprints201809.0322.v1↗
- Mehrdad Nikfarjam · 2 shared papers, 2018–2019 · strength 0.18
- Paper PAK inhibition by PF-3758309 enhanced the sensitivity of multiple chemotherapeutic reagents in patient-derived pancreat… PMID 31312349↗
- Paper The PAK Inhibitor PF-3758309 Promotes the Inhibitory Effects of Multiple Chemotherapeutic Reagents on Patient-Derived P… DOI 10.20944/preprints201809.0322.v1↗
- Kai Wang · 1 shared paper, 2019 · strength 0.10
- Jaswinder Singh Samra · 1 shared paper, 2018 · strength 0.09
- Angela S. Y. Chou · 1 shared paper, 2018 · strength 0.09
- Anthony James Gill · 1 shared paper, 2018 · strength 0.09
- Adnan M. Nagrial · 1 shared paper, 2018 · strength 0.09
- Kai Wang · 1 shared paper, 2018 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.